Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Heron Therapeutics (HRTX) Gets a Buy From Northland Securities
Heron Therapeutics Analyst Ratings
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Heron Therapeutics Analyst Ratings
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $5
Heron Therapeutics Analyst Ratings
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Heron Therapeutics Analyst Ratings
Rodman & Renshaw Initiates Coverage On Heron Therapeutics With Buy Rating, Announces Price Target of $7
Needham: Reiterates Heron Therapeutics (HRTX.US) rating, adjusted from buy to buy rating, target price of $5.00.
Heron Therapeutics Analyst Ratings
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
Needham: Reiterates Heron Therapeutics (HRTX.US) rating, adjusted from buy to buy rating, target price of $5.00.
Heron Therapeutics Analyst Ratings
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Heron Therapeutics Analyst Ratings
Capital One Initiates Coverage On Heron Therapeutics With Overweight Rating, Announces Price Target of $6